Leukemia Classification
Leukemia Research is an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies · For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions Posted: June 3, In a small study, vemurafenib (Zelboraf) and rituximab (Rituxan) helped 85% of participants stay in remission for nearly 3 years. The study involved 30 people with hairy cell leukemia that had come back after or had not responded to previous treatment As with most other malignant diseases, leukemia is more common in men than women, with more than 56% of all new diagnoses seen in men. Incidence estimates for total leukemia vary around tenfold between countries, ranging from –12 cases per persons per year among men and – cases per per year among women (Figure 1).Estimated Reading Time: 10 mins
History of Leukemia
As with most other malignant diseases, leukemia is more common in men than women, with more than 56% of all new diagnoses seen in men. Incidence estimates for total leukemia vary around tenfold between countries, ranging from –12 cases per persons per year among men and – cases per per year among women (Figure 1).Estimated Reading Time: 10 mins · For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions Posted: June 3, In a small study, vemurafenib (Zelboraf) and rituximab (Rituxan) helped 85% of participants stay in remission for nearly 3 years. The study involved 30 people with hairy cell leukemia that had come back after or had not responded to previous treatment Leukemia Research Reports (LRR), a companion title to Leukemia Research, is a peer-reviewed publication devoted to the rapid publication of short, high-quality papers related to a broad scope of therapeutic areas of hematology, including hematologic malignancies and other non-malignant diseases, View full aims & scope Related journals
CONTACT INFORMATION
· For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions Posted: June 3, In a small study, vemurafenib (Zelboraf) and rituximab (Rituxan) helped 85% of participants stay in remission for nearly 3 years. The study involved 30 people with hairy cell leukemia that had come back after or had not responded to previous treatment Leukemia Research is an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies Leukemia Research Reports (LRR), a companion title to Leukemia Research, is a peer-reviewed publication devoted to the rapid publication of short, high-quality papers related to a broad scope of therapeutic areas of hematology, including hematologic malignancies and other non-malignant diseases, View full aims & scope Related journals
As with most other malignant diseases, leukemia is more common in men than women, with more than 56% of all new diagnoses seen in men. Incidence estimates for total leukemia vary around tenfold between countries, ranging from –12 cases per persons per year among men and – cases per per year among women (Figure 1).Estimated Reading Time: 10 mins Leukemia Research is an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies · For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions Posted: June 3, In a small study, vemurafenib (Zelboraf) and rituximab (Rituxan) helped 85% of participants stay in remission for nearly 3 years. The study involved 30 people with hairy cell leukemia that had come back after or had not responded to previous treatment
As with most other malignant diseases, leukemia is more common in men than women, with more than 56% of all new diagnoses seen in men. Incidence estimates for total leukemia vary around tenfold between countries, ranging from –12 cases per persons per year among men and – cases per per year among women (Figure 1).Estimated Reading Time: 10 mins Leukemia Research is an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies · For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions Posted: June 3, In a small study, vemurafenib (Zelboraf) and rituximab (Rituxan) helped 85% of participants stay in remission for nearly 3 years. The study involved 30 people with hairy cell leukemia that had come back after or had not responded to previous treatment
No comments:
Post a Comment